patient subgroup...
corticosteroids: no corticosteroids: yes critical disease severe disease
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Immunosuppressants drugs - versus potential COVID-19 treatments - for COVID-19 severe or critically
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.92 [0.67, 1.26]< 1 23% 9 studies (9/-) 69.9 % some concern not evaluable moderate crucial - deaths 0.87 [0.69, 1.08]< 1 16% 13 studies (13/-) 90.0 % some concern low moderate crucial - deaths (time to event analysis only) 1.04 [0.78, 1.38]< 1 0% 3 studies (3/-) 39.8 % some concern not evaluable moderate crucial - clinical deterioration 0.48 [0.20, 1.20]< 1 6% 2 studies (2/-) 94.1 % some concern not evaluable moderate important - clinical improvement 1.40 [1.10, 1.78]> 1 30% 7 studies (7/-) 99.7 % some concern not evaluable moderate important - clinical improvement (14-day) 1.98 [1.05, 3.71]> 1 0% 2 studies (2/-) 98.3 % low not evaluable high important - clinical improvement (21-day) 1.50 [0.22, 10.08]> 1 0% 1 study (1/-) 66.1 % NA not evaluable important - clinical improvement (28-day) 1.33 [0.95, 1.87]> 1 0% 4 studies (4/-) 95.3 % some concern not evaluable moderate important - clinical improvement (7-day) 2.38 [0.38, 14.70]> 1 0% 1 study (1/-) 82.3 % NA not evaluable important - clinical improvement (time to event analysis only) 1.13 [0.92, 1.39]> 1 0% 3 studies (3/-) 87.3 % some concern not evaluable moderate important - death or ventilation 0.96 [0.65, 1.43]< 1 26% 3 studies (3/-) 57.8 % some concern not evaluable moderate important - hospital discharge 0.95 [0.79, 1.16]> 1 0% 2 studies (2/-) 31.3 % some concern not evaluable moderate important - mechanical ventilation 0.65 [0.37, 1.13]< 1 13% 4 studies (4/-) 93.7 % some concern not evaluable moderate important - radiologic improvement (14-day) 5.54 [1.01, 30.50]> 1 0% 1 study (1/-) 97.5 % NA not evaluable important - ICU admission 0.48 [0.25, 0.94]< 1 0% 1 study (1/-) 98.4 % NA not evaluable non important - recovery 1.30 [0.64, 2.66]> 1 9% 2 studies (2/-) 76.5 % low not evaluable high non important - 00 related AE (TRAE) 1.26 [0.14, 11.07]< 1 0% 2 studies (2/-) 41.9 % some concern not evaluable moderate important - serious adverse events 0.99 [0.75, 1.32]< 1 25% 7 studies (7/-) 52.0 % some concern not evaluable moderate important - adverse events 1.16 [0.91, 1.49]< 1 11% 8 studies (8/-) 11.6 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration:
